

**FULBRIGHT & JAWORSKI L.L.P.**

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5201  
FACSIMILE: 512/536-4598

WRITER'S INTERNET ADDRESS:  
GSHISHIMA@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER:  
512/536-3081



January 25, 2002

HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONDON  
HONG KONG

#6  
Linda  
2/28/02

FILE: UTSD:483USD1  
10107524

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, 20231, on the date below:	
January 25, 2002 Date	Steven L. Highlander

TECH CENTER 1600/2900

FEB 26 2002

RECEIVED  
BEST AVAILABLE COPY

**BOX MISSING PARTS**

Commissioner for Patents  
Washington, DC 20231

RE: *U.S. Patent Application No. 09/933,497 Entitled: IMMUNOGLOBULIN-LIKE DOMAINS WITH INCREASED HALF LIVES - by Elizabeth Sally Ward*

Commissioner:

Enclosed for filing in the above-referenced patent application is:

- (1) Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- (2) Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Dated October 25, 2001;
- (3) Statement as Required Under 37 C.F.R. § 1.821(f); Paper Copy of Sequence Listing; Computer Readable Form (CRF);
- (4) A check for \$55.00 as the fee for the one-month extension of time; and ✓
- (5) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

02/12/2002 BABRAHA1 00000124 09933497

01 FC:215


55.00 00

25120496.1

Commissioner for Patents  
January 25, 2002  
Page 2

If the check is inadvertently omitted, or the amount is insufficient, or should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, or should an overpayment be included herein, the Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski L.L.P. Account No.: 50-1212/10107524/SLH.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642


SLH/cpj  
Encl.: As stated

BEST AVAILABLE COPY



CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

January 25, 2002 Date	 Steven L. Highlander
--------------------------	-----------------------------------------------------------------------------------------------------------

0340 \$  
1600  
1644  
TECH CENTER 1600/2900

RECEIVED  
FEB 26 2002

PATENT

BEST AVAILABLE COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Elizabeth Sally Ward

Serial No.: 09/933,497

Filed: August 20, 2001

For: IMMUNOGLOBULIN-LIKE DOMAINS  
WITH INCREASED HALF LIVES

Group Art Unit: UNKNOWN

Examiner: UNKNOWN

Atty. Dkt. No.: UTSD:483USD1/SLH

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES DATED OCTOBER 25, 2001**

Commissioner for Patents  
Washington, D.C. 20231

Commissioner:

This paper is submitted in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated October 25, 2001 for which the two-month date for response was December 25, 2001.

A request for a one-month extension of time to respond is included herewith along with the required fee. This one-month extension will bring the due date to January 25, 2002, which is within the six-month statutory period. Should such request or fee be deficient or absent, consider this paragraph such a request and authorization to withdraw the appropriate fee under 37 C.F.R. §§ 1.16 to 1.21 from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10107524/SLH.

## RESPONSE TO NOTICE


Submitted herewith is a Statement As Required Under 37 C.F.R. § 1.821(f); paper copy of sequence listing and computer readable form (CRF) which comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures.

Attached as Exhibit A are copies of correspondence (April 1, 1999, September 15, 1999 and January 13, 2000) with the United States Patent and Trademark Office wherein we numerously filed a Statement as Required to Under 37 C.F.R. § 1.825(a) and (b) and Statement as Required Under 37 C.F.R. § 1.821(g); Sequence Listing; computer readable form (CRF) copy of the Sequence Listing and a separate paper copy.

**Applicants respectfully request that the Sequence Listing being filed at this time be handled with care and insure that the diskette is carefully handled in that this is the fourth time that applicant has submitted this information requested.**

Applicants believe that the attached documents fully respond to the Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures for this application.


Respectfully submitted,

  
Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201  
(512) 536-4598 (facsimile)

Date: January 25, 2002

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 536-3184

Date: January 25, 2002

BEST AVAILABLE COPY